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Abstract
PURPOSE—The purpose of this study was to assess the association between antidepressant use
and incident coronary heart disease (CHD) events in a sample of individuals without known
baseline heart disease.
PARTICIPANTS AND METHODS—We studied a group of 970 randomly-selected community-
dwelling adults in the 1995 Nova Scotia Health Survey, who were followed for up to ten years.
Antidepressant usage was classified according to class. Primary outcomes were acute coronary
syndrome hospitalizations or cardiac death, determined by centralized, standardized ratings.
RESULTS—During a follow-up period of ten years, there were 147 incident CHD events (139
acute coronary syndromes and 8 cardiac deaths) during the 8,129 person-years of observation
(incidence rate = 18.1 events/1000 person years). In a model controlling for age, sex, Framingham
risk score, time to last annual exam, aspirin exposure, and depressive symptoms, an increased risk
of CHD events was associated with tricyclic antidepressant exposure (adjusted hazard ratio, 2.10;
95% confidence interval, 1.09–4.06; p=0.027).
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CONCLUSION—In this prospective population-based study, exposure to tricyclic
antidepressants was associated with higher risk of first CHD events.
INTRODUCTION
Depression has been associated with worse prognosis in individuals with established
coronary heart disease and with the development of coronary heart disease.1 However, there
have been few population-based investigations testing the impact of antidepressant use on
long-term CHD incidence.2,3,4,5 In this report we present the results of a prospective
analysis of the relationship between antidepressant medication use and risk of incident CHD
during 10-year follow-up of a population-based cohort.
METHODS
SUBJECTS
The study sample included patients enrolled in the 1995 Nova Scotia Health Survey study, a
population-based survey by Heart Health Nova Scotia in partnership with the Nova Scotia
Department of Health. The targeted population consisted of all non-institutionalized Nova
Scotians age 45 and older, known to be CHD-free, whose names were listed in the Medical
Service Insurance register, the government-sponsored, universal health insurance plan. We
defined the period of follow-up for each participant as starting at the participant’s age at
baseline and extending until either his/her age at first CHD event or age on March 31, 2005
for those who did not have an event during the follow-up period.
At the home visit, the nurse requested all prescription and nonprescription medications and
supplements, and recorded the generic drug name, the brand name, the number of pills in the
bottle, the date of the prescription, and the dosing instructions. Drugs were coded using the
World Health Organization Nordic Anatomical, Therapeutic, and Chemical code
classification valid in 1995.6
The main outcome variable was incidence of nonfatal or fatal CHD, as categorized by the
International Classification of Diseases.7 All deaths are reported to provincial offices, which
in turn notify the national census bureau, Statistics Canada, which applies a nationally
consistent process of determining the underlying cause of death. Nonfatal CHD was
assessed by primary discharge hospital code, collected in the centralized, computerized,
single-payer medical system.
Depressive symptoms were assessed at baseline with the Center for Epidemiological Studies
Depression Scale.
Nurses visited the subjects at home for the baseline measures and recorded all prescription
medications. Antidepressants were categorized as TCAs, SSRIs and Others.
STATISTICAL ANALYSIS
Baseline characteristics of the participants were compared by use of antidepressant
medications and by drug class. Data are expressed as means and standard deviations, or
percentages. Multivariable proportional hazards models were used to estimate the hazard
ratio associated with antidepressant use, with adjustment for possible confounders including
Framingham risk score and depressive symptoms. All statistical analyses were performed
using SPSS statistical software version for Windows 16.0 (Chicago, IL).
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Of the 970 patients, 40 (4%) possessed at least one prescription for an antidepressant at
baseline (1995), and 930 did not. Baseline clinical characteristics are shown in Table 1.
Length of follow-up did not vary for the antidepressant class and nonuser categories. Of the
40 participants using an antidepressant, 14 were on selective serotonin reuptake inhibitors
(SSRIs), 25 were on tricyclic antidepressants (TCAs), and one patient was taking both.
During follow-up of ten years, there were 147 incident CHD events (139 acute coronary
syndromes and 8 cardiac deaths) during the 8,129 person-years of observation (incidence
rate = 18.1 events/1000 person years). In a proportional hazards model controlling for age,
sex, Framingham risk score, time to last annual exam, aspirin exposure, and baseline
depressive symptoms, TCA exposure predicted a higher risk of 10-year incident CHD events
(adjusted hazard ratio, 2.10; 95% confidence interval, 1.09–4.06; p<0.05) (Table 2). After
adjustment for the same factors, the association of SSRI exposure with CHD events was not
significant (relative risk 1.33, 95% CI 0.49–3.64).
DISCUSSION
In this population-based survey we found a statistically significant association between TCA
use and risk of 10-year incident CHD events. The relation between tricyclic use and incident
CHD events persisted after multivariable adjustment for possible confounders, including
annual visit, use of another cardioprotective medication (aspirin), the Framingham risk score
and depressive symptoms. As antidepressant use can be viewed as a marker for depressive
symptoms, our data support the existing evidence linking the presence of depression to
development of coronary heart disease. However, our data are also consistent with
cardiovascular harm associated with tricyclic use, this time with long-term follow-up.
Our findings substantiate the results of a previous study of 2247 union health plan members,
8 which reported a relative risk for myocardial infarction of 2.2 (95% CI 1.2–3.8) among
TCA users, although this study did not adjust for depressive symptoms. Our findings support
another observation of this study that identified no increased risk of MI with SSRI exposure.
Other similar investigations have been limited by short follow-up periods, usually not more
than 8 weeks in duration.9
In this observational study of 970 Nova Scotians without pre-existing CHD, we observed an
association between exposure to TCAs and incident CHD over a ten-year follow-up period.
This increased risk suggests a mechanism of cardiotoxicity independent of the well-known
arrhythmogenic effects of TCAs. Further research is indicated to determine the underlying
pathways between tricyclic exposure and increased incidence of CHD seen in long-term
follow-up in a general population.
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Table 1
Baseline Variables for the Canadian, Population-based Sample (N=970)
Variable Mean(SD) N
Age, y 61 (11.20)








2 year, % 149 days (15.4)
3 year, % 112 days (11.5)




Aspirin exposure, % 59 (6.1)
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Table 2







Sex of Participant Female (vs Male) 1.69(1.21–2.34) -
Age Per SD (1 SD = 11.20
yrs)
1.66 (1.42–1.93) -
Risk Score Per SD (1 SD = 3.88
points)
1.83 (1.57–2.13) -




Aspirin exposure 1.37(0.76–2.47) 1.13(0.65–1.96)
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